Use of intravenous immunoglobulin in pediatric practice

Zülfikar, Bulent; Koç, Başak

doi:10.5152/tpa.2014.2212

Cited by 4 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(DeLano et al, 2000;Feng et al, 2013;Foss et al, 2015;Jaggi et al, 2007;Li et al, 2005;Linker, 1983;Liu et al, 2007;Ober et al, 2004a;Raghavan et al, 1994;Roopenian and Akilesh, 2007;Sockolosky et al, 2014;Sockolosky and Szoka, 2015;Strauch et al, 2014;Swiercz et al, 2014;Vaccaro et al, 2005;Zülfikar and Koç, 2014) Fc-fusion for vaccination and pathogen neutralization (a) Use of Fc-fused to model antigens.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

A comprehensive review of the neonatal Fc receptor and its application in drug delivery

Martins

Kennedy

Santos

et al. 2016

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Section: Accepted Manuscriptmentioning

confidence: 99%

“…Depleting or reducing the IgG levels in serum in a pathological context is achieved through two main approved treatments: plasmapheresis and high dose IVIG (Linker, 1983;Zülfikar and Koç, 2014). However, the expense, extended course of delivery, and side effects of the treatment have been triggering efforts in the development of alternatives.…”

mentioning

confidence: 99%

A comprehensive review of the neonatal Fc receptor and its application in drug delivery

Martins

Kennedy

Santos

et al. 2016

Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…The mean frequency of AE seen during IVIG treatment was reported to be 20% changing from 1 to 81%. [7][8][9][10] Galli et al 19 reported 40% of AE seen in PID children. In addition, Dashti-Khavidaki et al 20 documented 216 AE (7.2%) in 3,004 infusions for 13 years.…”

Section: Discussionmentioning

confidence: 99%

“…[2][3][4][5][6] The frequency of adverse events seen in IVIG treatment varies between 1-81% with a mean value of 20%. [7][8][9][10] These are classified as early or late according to the time of occurrence of the reaction. 11 The most common early adverse events (AE) are fever, chills, headache, nausea, hypotension, myalgia, wheezing, back pain and rash.…”

mentioning

confidence: 99%

Immediate adverse reactions to intravenous immunoglobulin in primary immune deficiencies: a single center experience

Nain¹,

Kıykım²,

Kasap³

et al. 2020

Turk J Pediatr

View full text Add to dashboard Cite

Background and objective. Adverse reactions related to intravenous immunoglobulin (IVIG) infusions vary from 1 to 81%, with an average of 20%. They may be classified as immediate; occurring during the infusion itself or delayed; occurring after the infusion has been ceased. In the present study, we aimed to evaluate the frequency of immediate adverse reactions due to IVIG infusions in primary immune deficiency (PID) patients. Methods.The study population was composed of 109 patients. A total of 763 infusions were recorded for demographic data and adverse reactions.Results. The participants included 32 girls (29%) and 77 boys (71%). The mean age was 11.8 ± 5.7 years (0.6-33.5 years). Early adverse events (AE) were recorded in 34 (4.5%) among 763 IVIG infusions including 30 mild (88.2%), 3 moderate (8.8%) and 1 severe (2.9%). The most common immediate adverse reactions were fever (29.4%) and headache (29.4%). The risk of AE was higher among primary antibody deficiency (PAD), compared to combined immunodeficiency (OR 2.61, 95%CI 1.061-6.475; p = 0.037). Conclusions.Use of various intravenous immunoglobulin treatments should be considered with regard to side effect profiles observed. In our cohort, PID patient experienced mostly mild AE; PAD was associated with an increased risk of AE.

show abstract

“…Intravenous immunoglobulin therapy is primarily used as a replacement therapy for immunodeficient patients, but it can also be used for the treatment of many diseases, at high doses, due to its anti-inflammatory and immunoregulatory effects. 1 , 2 The indications for US Food and Drug Administration (FDA) approved IVIG use include several diseases, such as primary humoral immunodeficiency, immune thrombocytopenic purpura (ITP), Kawasaki disease (KD), chronic lymphocytic leukemia, and multifocal motor neuropathy. It has also been proven that IVIG therapy is beneficial for the treatment of many other diseases, such as Guillain-Barre syndrome (GBS), neonatal sepsis, neonatal blood type incompatibility, autoimmune hemolytic anemia (AHIA), and Stevens-Johnson syndrome.…”

mentioning

confidence: 99%

The use of intravenous immunoglobulin therapy in a tertiary pediatric hospital

Güngör

Yaralı

2020

SMJ

View full text Add to dashboard Cite

Objectives: To determine demographic features of patients provided intravenous immunoglobulin (IVIG) excluding replacement therapy in the inpatient services and to evaluate indications for IVIG, and side effects related to therapy. Methods: Patients who received IVIG therapy between January 2016 and August 2018 were retrospectively identified. The demographic features, diagnosis, IVIG dose, number of days they underwent IVIG therapy, and whether or not they experienced IVIG-related side effects were recorded. Results: A total of 186 patients were included in this study, and of these, 89 (47.8%) were females. The median age of all of the patients was 48.5 months old (range 13-120 months). When the IVIG indications Original Article were examined, the hematological disease group had the highest number of patients (n=73, 39.2%). The US Food and Drug Administration (FDA) labeled use rate was 45.7%. Side effects were seen in 15 (3.81%) of the 394 IVIG infusions, 2 of which were acute kidney failure and nausea/vomiting as delayed onset side effects. The rapid onset side effects included fever (n=5), headache (n=3), rash and redness (n=2), and pain in the infusion area, hypotension, and hypertension (n=1). Conclusion: Intravenous immunoglobulin preparations are used for the treatment of many diseases due to their immunoregulatory effects. In recent years, the use of IVIGs without FDA approval has been increasing.

show abstract

Use of intravenous immunoglobulin in pediatric practice

Cited by 4 publications

References 32 publications

A comprehensive review of the neonatal Fc receptor and its application in drug delivery

A comprehensive review of the neonatal Fc receptor and its application in drug delivery

Immediate adverse reactions to intravenous immunoglobulin in primary immune deficiencies: a single center experience

The use of intravenous immunoglobulin therapy in a tertiary pediatric hospital

Contact Info

Product

Resources

About